We also compared other indicators between baseline and 6 months posttreatment, including fasting insulin levels, insulin resistance indicators, hepatorenal biochemical parameters, and the prevalence of renal dysfunction and lipidemia disorder. This evidence concerns the gene INS and Insulin resistance.